Adamas Pharmaceuticals Announces Closing of Its Initial Public Offering

Apr 15, 2014

EMERYVILLE, Calif., April 15, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Adamas) (Nasdaq:ADMS), a specialty pharmaceutical company, today announced the closing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol "ADMS" on April 10, 2014. Adamas estimates net proceeds from the offering to be approximately $41.5 million after deducting underwriting discounts and commissions and estimated offering expenses.

Credit Suisse and Piper Jaffray acted as joint book-running managers for the proposed offering.  William Blair and Needham & Company acted as co-managers.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on April 9, 2014.

The offering was made only by means of a written prospectus forming part of the effective registration statement.  A copy of the final prospectus relating to these securities may be obtained from Credit Suisse Securities (USA) LLC, by mail at Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at +1 (800) 221-1037, or by e-mail at, or Piper Jaffray & Co., by mail at 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, or by telephone at +1 (800) 747-3924, or by e-mail at

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. Adamas achieves this by enhancing the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing its lead wholly owned product candidate, ADS-5102, for a complication of Parkinson's disease known as levodopa induced dyskinesia and as a treatment for chronic behavioral symptoms associated with traumatic brain injury.

SOURCE Adamas Pharmaceuticals, Inc.

News Provided by Acquire Media